Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study.

IF 7.6 2区医学 Q1 ONCOLOGY

NPJ Breast Cancer Pub Date : 2025-05-29 DOI:10.1038/s41523-025-00764-5

Jasper J L van Geel, Elisabeth M Jongbloed, Jasmine Moustaquim, Gonneke van der Schoor, A Elise van Leeuwen-Stok, Marcel Smid, Carolien H M van Deurzen, Saskia M Wilting, Jelle Wesseling, Gabe S Sonke, John W M Martens, Carolina P Schröder

{"title":"Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study.","authors":"Jasper J L van Geel, Elisabeth M Jongbloed, Jasmine Moustaquim, Gonneke van der Schoor, A Elise van Leeuwen-Stok, Marcel Smid, Carolien H M van Deurzen, Saskia M Wilting, Jelle Wesseling, Gabe S Sonke, John W M Martens, Carolina P Schröder","doi":"10.1038/s41523-025-00764-5","DOIUrl":null,"url":null,"abstract":"<p><p>Inflammatory breast cancer (IBC) is rare, with challenging diagnostics and unfavorable outcomes. Therefore, more molecular insight into IBC is needed. The comprehensive Dutch prospective INFLAME registry related IBC follow-up and treatment to histopathology and molecular analysis. Of consecutive patients, nationwide identified with newly diagnosed IBC, clinicopathological, treatment and outcome data were collected. Histopathology and RNA-sequencing were related to outcome. 125 IBC patients were enrolled. Forty-one (34%) patients had HER2 + , and 31 (25%) had triple-negative IBC. The estimated 3-year OS was 78% in M0 IBC and 29% in M1. PFS was worst in triple-negative IBC (median 7.9 vs 16.3 and 15.8 months in M1 HER2+ and HR + /HER2- IBC). DFS and OS in M0 IBC were better with guideline-concordant trimodal therapy than without (HR 0.15 and 0.15; p = 0.000005 and 0.00038). The unique prospective INFLAME confirms unfavorable IBC characteristics and outcomes. International efforts may support guideline adherence and identify IBC-specific targets.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"48"},"PeriodicalIF":7.6000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12122667/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Breast Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41523-025-00764-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Inflammatory breast cancer (IBC) is rare, with challenging diagnostics and unfavorable outcomes. Therefore, more molecular insight into IBC is needed. The comprehensive Dutch prospective INFLAME registry related IBC follow-up and treatment to histopathology and molecular analysis. Of consecutive patients, nationwide identified with newly diagnosed IBC, clinicopathological, treatment and outcome data were collected. Histopathology and RNA-sequencing were related to outcome. 125 IBC patients were enrolled. Forty-one (34%) patients had HER2 + , and 31 (25%) had triple-negative IBC. The estimated 3-year OS was 78% in M0 IBC and 29% in M1. PFS was worst in triple-negative IBC (median 7.9 vs 16.3 and 15.8 months in M1 HER2+ and HR + /HER2- IBC). DFS and OS in M0 IBC were better with guideline-concordant trimodal therapy than without (HR 0.15 and 0.15; p = 0.000005 and 0.00038). The unique prospective INFLAME confirms unfavorable IBC characteristics and outcomes. International efforts may support guideline adherence and identify IBC-specific targets.

Abstract Image

查看原文本刊更多论文

炎性乳腺癌的临床病理和分子特征，前瞻性炎症登记研究。

炎性乳腺癌（IBC）是罕见的，具有挑战性的诊断和不利的结果。因此，需要对IBC进行更多的分子研究。荷兰全面的前瞻性INFLAME登记与IBC随访和治疗有关，包括组织病理学和分子分析。在全国范围内确定为新诊断IBC的连续患者中，收集临床病理、治疗和结局数据。组织病理学和rna测序与结果相关。125名IBC患者入组。41例（34%）患者为HER2 +， 31例（25%）患者为三阴性IBC。估计3年OS在M0 IBC中为78%，在M1中为29%。三阴性IBC患者PFS最差（中位数为7.9个月，M1 HER2+和HR + /HER2- IBC患者为16.3个月和15.8个月）。M0型IBC患者接受符合指南的三模式治疗的DFS和OS优于未接受治疗的患者(HR分别为0.15和0.15；P = 0.000005和0.00038)。独特的前瞻性INFLAME证实了IBC的不利特征和结果。国际上的努力可能会支持指南的遵守，并确定ibc特定的目标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

NPJ Breast Cancer Medicine-Pharmacology (medical)

CiteScore

10.10

自引率

1.70%

发文量

122

审稿时长

9 weeks

期刊介绍： npj Breast Cancer publishes original research articles, reviews, brief correspondence, meeting reports, editorial summaries and hypothesis generating observations which could be unexplained or preliminary findings from experiments, novel ideas, or the framing of new questions that need to be solved. Featured topics of the journal include imaging, immunotherapy, molecular classification of disease, mechanism-based therapies largely targeting signal transduction pathways, carcinogenesis including hereditary susceptibility and molecular epidemiology, survivorship issues including long-term toxicities of treatment and secondary neoplasm occurrence, the biophysics of cancer, mechanisms of metastasis and their perturbation, and studies of the tumor microenvironment.